FDA Panel Unanimously Backs Moderna's mRNA Flu Shot—A First Since 2023

A key U.S. Food and Drug Administration advisory committee has unanimously recommended Moderna's mRNA-based influenza vaccine for adults aged 50 and over. The decisive 9-0 vote, reported by NPR, marks the first time the panel has recommended any new vaccine since 2023 and signals a major step in moving mRNA technology beyond its crisis-mode deployment for COVID-19.

This is the moment the biotech world has been waiting for. The success of mRNA during the pandemic was built on speed and necessity. This unanimous recommendation, however, comes from a standard, non-emergency review process. It suggests the underlying platform is ready to compete on its own merits in the massive, established market for annual flu shots.

Unanimous Support After Agency Gridlock

The committee's clean sweep endorsement is particularly significant given the backstory of its review. According to Ars Technica, the vaccine's path to the committee was stalled in February when a Trump-appointed official allegedly refused to even review the application. That a politically fraught process has now culminated in a unanimous scientific consensus indicates the data for the vaccine is compelling.

All nine members of the advisory panel voted in favor of the vaccine's approval. While the FDA is not obligated to follow its advisory committees' recommendations, it typically does. This vote effectively clears the last major scientific hurdle for Moderna's shot, putting the final decision in the hands of the agency's leadership.

The Next Generation of Flu Shots

The core promise of an mRNA flu vaccine isn't just about another option; it's about a better, faster process. Traditional flu vaccines are grown in chicken eggs, a slow and sometimes imprecise method that requires health officials to predict which flu strains will be dominant many months in advance. mRNA vaccines, by contrast, can be designed and manufactured much more quickly, theoretically allowing for a shot that is better matched to the strains actually circulating during flu season.

This vote puts Moderna on a path to directly challenge long-time flu shot manufacturers like Sanofi and GSK. The unanimous recommendation provides a powerful marketing tool and a vote of confidence that could ease vaccine hesitancy among a public that still primarily associates mRNA with the COVID-19 pandemic. The pattern is clear: a technology forged in a crisis is now being normalized through the FDA's most rigorous peacetime processes. The question is no longer if mRNA can work for other illnesses, but how quickly it will be deployed against them.